Endurance Wealth Management Inc. grew its position in Novartis AG (NYSE:NVS) by 51.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 493 shares of the company’s stock after buying an additional 168 shares during the quarter. Endurance Wealth Management Inc.’s holdings in Novartis were worth $47,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Primecap Management Co. CA increased its position in Novartis by 7.4% in the 2nd quarter. Primecap Management Co. CA now owns 25,617,640 shares of the company’s stock valued at $2,339,147,000 after acquiring an additional 1,760,424 shares during the period. Bank of America Corp DE increased its position in Novartis by 1.3% in the 2nd quarter. Bank of America Corp DE now owns 9,166,269 shares of the company’s stock valued at $836,972,000 after acquiring an additional 115,613 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Novartis by 3.1% in the 3rd quarter. Fisher Asset Management LLC now owns 8,314,984 shares of the company’s stock valued at $722,572,000 after purchasing an additional 247,749 shares during the last quarter. State Street Corp boosted its stake in shares of Novartis by 1.8% in the 3rd quarter. State Street Corp now owns 2,721,543 shares of the company’s stock valued at $236,502,000 after purchasing an additional 48,335 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of Novartis by 2.5% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 2,538,794 shares of the company’s stock valued at $220,621,000 after purchasing an additional 61,474 shares during the last quarter. Institutional investors own 10.62% of the company’s stock.
A number of equities research analysts have recently commented on NVS shares. ValuEngine raised shares of Novartis from a “sell” rating to a “hold” rating in a research note on Saturday, October 19th. Cowen reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Novartis in a research note on Friday, October 25th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $93.34.
Shares of NYSE NVS opened at $94.38 on Wednesday. The firm has a market cap of $215.11 billion, a PE ratio of 18.54, a P/E/G ratio of 1.94 and a beta of 0.59. Novartis AG has a 12-month low of $74.70 and a 12-month high of $95.66. The company’s fifty day simple moving average is $93.59 and its 200 day simple moving average is $90.22. The company has a quick ratio of 0.73, a current ratio of 0.95 and a debt-to-equity ratio of 0.42.
Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 22nd. The company reported $1.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.31 by $0.10. The business had revenue of $12.17 billion for the quarter, compared to analyst estimates of $11.67 billion. Novartis had a net margin of 24.43% and a return on equity of 20.86%. Novartis’s revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.32 earnings per share. On average, equities analysts predict that Novartis AG will post 5.23 earnings per share for the current year.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Featured Story: How prevalent are 12b-1 fees?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.